Today: 25 January 2026
Subscribe
Browse Category

Business Updates News 14 October 2025 - 28 October 2025

Helmet Maker Studds Launches ₹455 Cr IPO – Grey Market Predicts ~10% Listing Pop

Helmet Maker Studds Launches ₹455 Cr IPO – Grey Market Predicts ~10% Listing Pop

India’s busiest IPO week rolls on with Studds following Orkla and Lenskart to market. With the issue entirely an OFS, all ₹455+ crore will go to existing shareholders – primarily promoters Madhu and Sidhartha Khurana and family investors Indiatimes Freepressjournal. “Studds will offer 78 lakh equity shares in the primary market,” ETMarkets reports Indiatimes, and “all proceeds will go to…
28 October 2025
···
Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Lone Star Buyout Details Hillenbrand (NYSE: HI) announced on Oct. 15 that it will be acquired by Lone Star Funds in an all-cash deal at $32.00 per share Hillenbrand. At this price, the transaction’s enterprise value is roughly $3.8 billion, including Hillenbrand’s debt. The board said it reviewed multiple strategic options and unanimously determined the offer “is in the best interest of…
15 October 2025
····
Polaris Shocks Market: Sells Indian Motorcycle to Private Equity; Stock Surges Over 10%

Polaris Shocks Market: Sells Indian Motorcycle to Private Equity; Stock Surges Over 10%

Deal Details and Strategic Rationale Polaris’s surprise announcement comes after years of owning Indian Motorcycle (acquired in 2011) and ultimately retiring its rival Victory brand in 2017. In a press release, Polaris explained it will “separate Indian Motorcycle into a standalone business” to let each company “move faster” with sharper focus Polaris Polaris. Polaris CEO Mike Speetzen said the move…
14 October 2025
···
1 … 7 8 9

Stock Market Today

  • Ascendis Pharma (ASND) Shares Surge Amid Growth Optimism and Valuation Debate
    January 25, 2026, 3:53 AM EST. Ascendis Pharma (NasdaqGS:ASND) has posted a 14.36% gain over seven days and an 83.61% total return in the past year, rekindling investor interest. The stock trades at $235.39, below several valuation estimates including a $270.52 target based on long-term growth forecasts. Biotech catalysts like regulatory progress for TransCon CNP and promising trial data support expectations for multi-billion euro peak sales, underpinning this upside. However, risks remain from potential slower product uptake, pricing pressures, and competitive challenges. A discounted cash flow (DCF) model indicates an even higher fair value around $864.54, reflecting aggressive optimism about future cash flows. Investors are encouraged to weigh these forecasts against execution risks amid evolving market conditions.
Go toTop